Who We Are
NK Immuno T is developing an investigational program that brings together immune biology, exploratory biomarkers and combination therapy research.
A Focused Company Advancing ALS Research
Our mission is to develop a more targeted therapeutic approach for people living with ALS.
Focused on the Evidence Needed for Future Development
NK Immuno T is building an investigational program around immune biology, exploratory biomarkers and combination therapy research.
Our Foundation
Our program builds on technology originating at UCLA and research into immune dysregulation in ALS.
Our Priorities
Validate the biomarkers, evaluate the therapeutic approach and build the evidence needed to guide future clinical development.
Our Scientific Foundation
Built on UCLA-origin technology, published ALS research and early foundation support.
Licensed UCLA Technology
Technology originating in UCLA laboratories provides the intellectual-property foundation for our biomarker-guided development program.
Calcagnini ALS Foundation
Early foundation funding supported published ALS studies and continuing research into immune dysregulation and therapeutic approaches.
Continuing Her Legacy
Dr. Jewett passed away on June 15, 2025. We honor her legacy by advancing this research with rigorous validation and a focus on patients.